RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Fibrosi polmonare e cutanea nella sclerodermia: meccanismi patogenetici, diagnostica precoce ed effetti di farmaci antifibrogenetici
• 2 - RUOLO DEI RECETTORI ATTIVATI DALLE PROTEASI (PAR)- 1 e 2 NELL'INFIAMMAZIONE ED IN PROCESSI FIBROTICI AD ESSA CORRELATI.
• 3 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 4 - FUMO DI TABACCO, INFIAMMAZIONE E CANCRO DEL POLMONE: ASPETTI MOLECOLARI, BIOLOGICI, CLINICI E ANATOMOPATOLOGICI
• 5 - RUOLO DELLE CELLULE DENDRITICHE, DELLE CITOCHINE E DEGLI ORMONI STEROIDEI SESSUALI NELLA STORIA NATURALE DELLE MALATTIE EPATICHE CRONICHE
• 6 - L'apoptosi nei processi immunitari ed infiammatori: caratterizzazione di meccanismi molecolari e cellulari finalizzata a interventi terapeutici innovativi.
• 7 - Epatopatia steatosica non alcolica : studio dei fattori metabolici, genetici e virologici responsabili del danno epatico e della sua evoluzione
• 8 - ANALISI DEI MECCANISMI TRASCRIZIONALI NEI PROCESSI DI SOPRAVVIVENZA, PROLIFERAZIONE E PROGRESSIONE DELLE EMOPATIE MALIGNE
• 9 - Il sistema GITR/GITRL nelle malattie a patogenesi autoimmunitaria/infiammatoria: un bersaglio per la terapia farmacologica
• 10 - RUOLO DEI MECCANISMI DI SEGNALE CELLULARE E DELLE SPECIE REATTIVE DELL'OSSIGENO E DELL'AZOTO NELL'INVECCHIAMENTO CELLULARE E NELLA CRESCITA NEOPLASTICA.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • MALATTIE DELL'APPARATO RESPIRATORIO

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Sicilia

Bibliografia

1. Green F.H.I. Overview of pulmonary fibrosis Chest 2002; 122: 334s-339s
2. Irifune K, Yokoyama A et al. T-helper 1 cells induce alveolitis but do not lead to pulmonary fibrosis in mice Eur Respir J 2003;
21: 11-18
3. Smith R.E., Strieter R.M., Phan S.H., and Kunkel S.L. C-C Chemokines: Novel Mediators of the Profibrotic Inflammatory
Response to Bleomycin Challenge. Am J Respir Cell Mol Biol 1996; 15: 693-702.
4. Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication? The Journal of Clinical Investigation
2001; 107 (12): 1501-02.
5. Smith R.E., Hogaboam C.M., Strieter R.M., Lukacs N.W., and Kunkel. Cell-to-cell and cell-to-matrix interactions mediate
chemokine expression: an important component of the inflammatory lesion. Journal of Leukocyte Biology 1997; 62: 612-619.
6. Selman M., King T.E., and Pardo A. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis
and Implications for Therapy. Ann. Intern. Med. 2001; 134: 136-151.
7. Keane M.P., Arenberg D.A., Lynch J.P., Whyte R.I, Iannettoni M.D., Burdick M.D., Wilke C.A., Morris S.B., Glass M.C.,
DiGiovine B., Kunkel S.L., and Strieter R.M. The CXC Chemokines, IL-8 and IP-10, Regulate Angiogenic Activity in Idiopathic
Pulmonary Fibrosis. The Journal of Immunology 1997; 159: 1437-1443.
8. Rolfe M.W., Kunkel S.L., Standiford T.J., Orringer M.B., Phan S.H., Evanoff H.L., Burdick M.D., and Strieter R.M. Expression
and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am. J. Physiol. 1992; 263: L536-L545.
9. Flaherty KR, Travis WD et al. Histopathologic variability in usual and non specific interstitial pneumonias Am J Respir Crit Care
Med 2001; 164: 1722-1727
10. Majumdar S, Li D et al.Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with
systemic sclerosis-A quantitative study of open lung biopsies Eur Respir J J 1999; 14: 251-257
11. Serpieer H, Gillery P et al. Antagonistic effects of interferon- and interleukin-4 on fibroblast cultures J Invest
Dermatol 1997; 109: 158-162
12. Costabel U. The alveolitis of hypersensivity pneumonitis Eur Respir J 1988; 1: 5-9
13. Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease Curr Opin Pulm Med 2001; 7: 255-261
14. Mosman TR, Li L et al.Functions of CD8 T-cell subsets secreting different cytokine patterns Semin Immunol 1997; 9: 87-92
15. Huang TJ, MacAry PA et al. Effect of CD8 T-cell depletion on bronchial hyperresponsiveness and inflammation in sensitised and
allergen-exposed Brown-Norway rats Immunology 1999; 96: 416-423
16. Wallace WAH, Ramage EA et al. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of
patients with cryptogenic fibrosing alveolitis (CFA) Clin Exp Immunol 1995; 101: 436-441
17. Ziesche R, Hofbauer EBS et al. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone
in patients with idiopathic pulmonary fibrosis New Engl J Med 1999; 341: 1264-1269
18. Sime PJ, O’Reilly KMA. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment Clin Immunology
2001; 99/3: 308-319
19. Lukacs NW, Hogaboam C et al. Type 1/Type 2 cytokine paradigm and the progression of pulmonary fibrosis Chest 2001; 120:
5s-8s
20. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity Immunity 2000; 12: 121-127
21. Rossi D, Zlotnik A. The biology of chemokines and their receptors Annu Rev Immunol 2000; 18: 217-242
22. Mackay CR. Chemokines: immunology’s high impact factors Nature Immunol 2001; 2: 95-101
23. Thelen M. Dancing to the tune of chemokines Nature Immunol 2001; 2: 129-134
24. D’Ambrosio D, Mariani M et al. Chemokines and their receptors guiding T lymphocyte recruiment in lung inflammation Am J
Respir Crit Care Med 2001; 164: 1266-1275
25. Agostini C, Cassatella M et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions J Immunol 1998; 161:
6413-6420
26. Moller DR, Forman JD et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary
sarcoidosis J Immunol 1996; 56: 4952-4960
27. Sinigaglia F. IL-12 in lung diseases Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 122-124
28. Iida K, Kadota J et al. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis Thorax 1997; 52:
431-437
29. Kodama N, Yamaguchi E et al. Expression of RANTES by bronchoalveolar lavage cells in nonsmoking patients with interstitial
lung diseases Am J Respir Cell Mol Biol 1998; 18: 526-531
30. Bonecchi R, Bianchi G et al. Differential expression of chemokine receptors and chemotactic responsiveness of Th1 and Th2 cells
J Exp Med 1998; 187: 129-134
31. Loetscher P, Uguccioni M et al. CCR5 is characteristic of Th1 lymphocytes Nature 1998; 391: 344-345
32. Strieter RM, Belperio JA et al. CXC chemokines in angiogenesis related to pulmonary fibrosis Chest 2002; 122:298s-301s
33. Luster AD. Mechanism of disease: chemokines-chemotactic cytokines that mediate inflammation N Engl J Med 1998; 338:
436-445
34. Lukacs NW, Oliveira SH et al. Chemokines and asthma: redundancy of function or a coordinated effort? J Clin Invest 1999; 104:
995-999
35. Cavarra E, Martorana PA, Bartalesi B, Fineschi S, Gambelli F,Lucattelli M, Ortiz L, Lungarella G. 2001. Genetic deficiency of
alpha1-PI in mice influences lung responses to bleomycin. Eur Respir J 17:474-480.
36. Chen ES, Greenlee BM, Wills-Karp M, Moller DR. 2001. Attenuation of lung inflammation and fibrosis in
interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 24:545-55.
37. Chignard M, Renesto P. 1994. Proteinases and cytokines in neutrophil and platelet interactions in vitro. Possible relevance to
the adult respiratory distress syndrome. Ann N Y Acad Sci 725:309-322.
38. Gauldie J, Jordana M, Cox G. 1993. Cytokines and pulmonary fibrosis. Thorax 48:931-935.
39. Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin
in mice. 2000. Am J Respir Crit Care Med 162:225-231.
40.Haston CK, Travis EL. 1997. Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor
implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 57:5286-91.
41. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, King TM, Weil MM, Newman RA, Amos CI, Travis EL. 2002.
Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 11:1855-63.
42 Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, Lungarella G, Brody A, Friedman M. 1998. Connective tissue
growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 275:L365-L367.
43. Jin FY, Nathan C, Radzioch D, Ding A. 1997. Secretory leukocyte protease inhibitor: a macrophage product induced by and
antagonistic to bacterial lipopolysaccharide. Cell 88:417-426.
44. MacNee W, Rahman I. 1995. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 50 Suppl 1:S53-S58.
45. MacNee W. 2000. Oxidants/Antioxidants and COPD. Chest. 117:303S-317S.
46. Verleden GM, du Bois RM, Bouros D et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of
unknown causes. Eur Respir J 2001; 18: Suppl 32, 17s-29s
47. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis 2002;
19: 83-95
48. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. Eur Respir J 2000:16: 768 – 780
49. Niimi T, Tomita H, Sato S et al. Vitamin D receptor gene polymorphisms in patients with sarcoidosis. Am J Respir Crit Care Med
1999; 160: 1107 – 1109

Parole Chiave

FIBROBLASTI; CHEMOCHINE; BLEOMICINA; FIBROSI; SARCOIDOSI; LINFOCITA; TH1; TH2; GENETICA